Switching From Semaglutide to Cagrisema in Type 2 Diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how people with type 2 diabetes tolerate switching from a weekly semaglutide injection (like Ozempic or Wegovy) to a new experimental medicine called Cagrisema. The goal is to see if the switch is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older at the time of signing the consent form.
- You must have had a type 2 diabetes diagnosis for at least 6 months.
- You must be currently taking a branded semaglutide injection (Ozempic or Wegovy) once weekly, and you cannot be using a compounded version.
- Your blood sugar level (HbA1c) must be between 6.5% and 10.5%, without other diabetes medications unless you are on metformin or an SGLT2 inhibitor.
- Your body mass index (BMI) must be 25 kg/m² or higher.
- You must not be pregnant, breastfeeding, or planning to become pregnant.
- You must not have significant kidney problems (eGFR less than 30).
- You must not have used any other weight-loss or diabetes medications in the past 3 months (except short-term insulin for up to 14 days).
- You must not have unstable diabetic retinopathy or macular edema confirmed by a recent eye exam.
- Your body weight must have been stable (no more than 5% change) in the past 3 months.
- You must be willing to stop using any personal continuous glucose monitoring (CGM) device for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CagriSema to see if it can lower blood sugar and help with weight loss in children and teens with type 2 diabetes. It compares the medicine to a placebo (a look-alike with no active drug) over several months.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This study compares two newer once-weekly injectable medicines to see which one works better for lowering blood sugar in people with type 2 diabetes. You may join if your blood sugar is not well controlled on your current diabetes pills.
This study tests whether a new combination medication called CagriSema (in two different doses) helps people with obesity lose weight. You may qualify if you're 18 or older, have a BMI of 35 or higher, and either don't have type 2 diabetes or have it well-controlled.
This study tests a new medicine called zenagamtide for adults with overweight or obesity, with or without type 2 diabetes, who are currently taking semaglutide. The goal is to see how well people tolerate switching from semaglutide to the new treatment.
This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.